<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20090824103932+02'00'</creation_date><modification_date>D:20090824103934+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-285_h_a_dec_8.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>commission of the european communities</p><p>brussels, 20.8.2009 c(2009)6581</p></section><section><header>commission decision of 20.8.2009 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;apidra - insulin glulisine&quot;, granted by decision c(2004)3653</header><p>(only the german text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 20.8.2009 
 on the renewal of the marketing authorisation for the medicinal product for human 
 use &quot;apidra - insulin glulisine&quot;, granted by decision c(2004)3653 
 (text with eea relevance)</header><p>the commission of the european communities, having regard to the treaty establishing the european community, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, and in particular article 10(2) thereof, having regard to the application submitted by sanofi-aventis deutschland gmbh, on 12 
 february 2009, under article 14(2) of regulation (ec) no 726/2004 with a view to the 
 renewal of the marketing authorisation for the medicinal product &quot;apidra - insulin 
 glulisine&quot; 
 having regard to the opinion of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 29 may 2009, 
 having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 2, and in particular article 61(3) thereof, 
 whereas: 
 (1)</p><p>on the basis of a re-evaluation by the agency of the risk-benefit balance 
 following the consideration of a consolidated file, it appears that the medicinal 
 product &quot;apidra - insulin glulisine&quot;, entered in the community register of 
 medicinal products under number(s) eu/1/04/285/001-036 and authorised by 
 commission decision c(2004)3653 of 27 september 2004, complies with the 
 requirements set out in directive 2001/83/ec of the european parliament and of 
 the council of 6 november 2001 on the community code relating to medicinal 
 products for human use
 3.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 311, 28.11.2001, p. 67. 3 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>(2) the marketing authorisation which expires on 29 september 2009 should 
 therefore be renewed. 
 (3)</p><p>sanofi-aventis deutschland gmbh submitted, under article 61(3) of directive 
 2001/83/ec, a notification(s) for changes to an aspect of the labelling or the 
 package leaflet, which has (have) not yet been included in decision c(2004)3653 
 of 27 september 2004. 
 (4)</p><p>the measures provided for in this decision are in accordance with the opinion of 
 the standing committee on medicinal products for human use, 
 has adopted this decision: 
 article 1 the marketing authorisation granted by decision c(2004)3653 of 27 september 2004 which expires on 29 september 2009 is renewed. 
 article 2 decision c(2004)3653 is amended as follows: 1) the following list of notifications for changes to an aspect of the labelling or the 
 package leaflet is added to the updated marketing authorisation; 
 application number 
 annex (eu numbers affected) 
 emea/h/c/557/n/21 
 iiia (eu/1/04/285/001-036)</p><p>
 2) annex i is replaced by the text set out in annex i to this decision; 
 3) annex ii is replaced by the text set out in annex ii to this decision; 
 4) annex iii is replaced by the text set out in annex iii to this decision.</p></section><section><header>en</header><p>4</p></section><section><header>en</header><p>article 3 this decision is addressed to sanofi-aventis deutschland gmbh, d-65926 frankfurt am main, deutschland. 
 done at brussels, 20.8.2009 
 for the commission heinz zourek 
 director-general</p></section></body></xml>